We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Tissue Proteomic Alliance Announced by Expression Pathology and ORIDIS Biomed

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Tissue Proteomic Alliance Announced by Expression Pathology and ORIDIS Biomed"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Expression Pathology Inc. and ORIDIS Biomed GmbH (Graz, Austria) have announced a strategic alliance to offer tissue microproteomic capabilities for protein biomarker discovery and validation.

The relationship combines Expression Pathology's proprietary Liquid Tissue® and DIRECTOR™ technologies, which enable mass spectrometry-based discovery and measurement of protein biomarkers in archival tissue, with ORIDIS Biomed's TISSOMICS™ research platform for high-throughput analysis of healthy and diseased patient tissue and its access to formalin-fixed tissue samples associated with longitudinal clinical and pathology information.

"We are pleased to enter into a strategic alliance with ORIDIS Biomed", said Casey Eitner, CEO, Expression Pathology. "This alliance will provide a powerful new option for drug and diagnostic developers to identify and measure protein biomarkers that relate to specific disease progression, drug response, and toxicity."

"We expect this partnership with Expression Pathology to serve the rapidly growing needs in tissue micro-proteomics", added Dr Peter Hecht, CEO ORIDIS Biomed.

"This partnership provides a unique opportunity to mine tissue archives with detailed clinical outcomes and pathology data by mass spectrometry and state-of-the-art pathology techniques."

Under the terms of the agreement both parties will offer collaborative research capabilities and services to biopharmaceutical, diagnostic and academic clients. Each party will also serve as a business development agent to its partner's technologies in its domestic geographical markets.